- Home
- ELVN vs NEO Comparison
ELVN vs NEO Comparison
Compare ELVN & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | NEO |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ELVN | NEO |
|---|---|---|
| Price | $17.85 | $12.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $41.20 | $11.38 |
| AVG Volume (30 Days) | 809.4K | ★ 1.7M |
| Earning Date | 11-12-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $709,162,000.00 |
| Revenue This Year | N/A | $10.90 |
| Revenue Next Year | N/A | $9.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $13.30 | $4.72 |
| 52 Week High | $25.37 | $19.12 |
Technical Indicators
Market Signals| Indicator | ELVN | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 68.27 |
| Support Level | $15.71 | $11.46 |
| Resistance Level | $17.58 | $12.19 |
| Average True Range (ATR) | 1.41 | 0.40 |
| MACD | -0.30 | -0.05 |
| Stochastic Oscillator | 32.86 | 99.53 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.